Emergent Biosolutions and TLV in Joint Venture to develop Pandemic Flu Vaccine

11 Aug 2010

Temasek Life Sciences Ventures Pte Ltd (TLV) and Emergent BioSolutions Inc. (NYSE:EBS) today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, crossprotective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.

Share